Protara Therapeutics (TARA) Accumulated Expenses (2013 - 2026)

Protara Therapeutics (TARA) has reported Accumulated Expenses for 14 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 37.8% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (up 37.8% YoY), while the FY2025 annual figure was $2.7 million, down 2.08% from the prior year.
• Accumulated Expenses grew to $3.6 million in Q1 2026 per TARA's latest filing, from $2.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.6 million in Q1 2026 and bottomed at $440000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $2.3 million across 5 years, with a median of $2.4 million in 2022.
• Annual changes were most pronounced in 2022 — Accumulated Expenses surged 2688.46% — and 2023, when it plunged 86.41%.
• Protara Therapeutics' Accumulated Expenses stood at $3.2 million in 2022, then slumped by 86.41% to $440000.0 in 2023, then jumped by 522.73% to $2.7 million in 2024, then dropped by 2.08% to $2.7 million in 2025, then soared by 35.18% to $3.6 million in 2026.
• Business Quant data shows TARA's Accumulated Expenses at $3.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.2 million in Q3 2025.